Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Q-linea AB ( (SE:QLINEA) ).
Q-linea AB’s nomination committee has proposed a largely unchanged board for the 2026 annual general meeting, with the addition of two new members, investment manager Öystein Engebretsen and Medistim CEO Kari Krogstad, while current director Karin Fischer has declined re-election. The committee recommends re-electing Johan Bygge as chairman and Mario Gualano as vice chairman, confirms all proposed directors as independent of management and most as independent of major shareholders, proposes reappointment of Öhrlings PricewaterhouseCoopers as auditor, and leaves board and committee fees unchanged, signaling governance continuity as the company advances its infection diagnostics strategy.
The nomination committee, chaired by Engebretsen and including several current board representatives, will publish its full rationale and detailed director information on Q-linea’s website at least three weeks before the meeting. The proposed stable governance, combined with the financial and biomedical expertise of the new nominees, is intended to support Q-linea’s efforts to strengthen its position in rapid antibiotic susceptibility testing and its broader role in addressing antimicrobial resistance in global healthcare markets.
The most recent analyst rating on (SE:QLINEA) stock is a Sell with a SEK24.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Swedish infection diagnostics company focused on rapid solutions for diagnosing and treating infectious diseases. Its core competence is rapid Antibiotic Susceptibility Testing, with its flagship ASTar® system delivering automated, phenotypic results from positive blood cultures in about six hours. By shortening time to optimal antibiotic therapy, Q-linea aims to improve sepsis outcomes and combat antimicrobial resistance.
YTD Price Performance: -6.68%
Average Trading Volume: 14,126
Technical Sentiment Signal: Sell
Current Market Cap: SEK433.4M
Find detailed analytics on QLINEA stock on TipRanks’ Stock Analysis page.